Wyeth Ltd operates in the Pharmaceutical preparations sector. Wyeth Limited is engaged in oral contraceptives and hormone therapy. The businesses of the Company is consists of Pharmaceuticals and Other businesses. Pharmaceuticals segment comprise of Formulations. Formulations comprise of Oral Contraceptives, Hormone Replacement Therapy, Antibiotics, Vaccines, Steroids and other prescription medicines. Others comprise of OTC pharmaceuticals, Cosmetics and other allied consumer products. In the field of anti-infectives, the Company launched Warclav (amoxicillin-clavulanate combination. In the macrolides segment, the Company launched VICON (Azithromycin tablets). During the fiscal year ended March 31, 2011, the Company launched Prevenar 13, which protects children against 13 types of disease causing Streptococcus pneumonia bacteria. Prevenar 13 offers a coverage against Streptococcus pneumonia serotypes than that offered by the standard Prevenar Vaccine (PCV 7). It is launching Branded Value Offerings (BVOs) in women's health and anti-infectives. In our complete report available for purchase the company is compared to: Indoco Remedies Ltd, Aarti Drugs Limited and Granules India Limited.